Prior A, Whorwell P J
Dept of Medicine, University Hospital of South Manchester.
Gut. 1987 Nov;28(11):1510-3. doi: 10.1136/gut.28.11.1510.
A double blind placebo controlled trial of ispaghula husk in 80 patients with irritable bowel syndrome is reported. Global assessment judged treatment to be satisfactory in 82% of patients receiving ispaghula and 53% of the placebo group (p less than 0.02). Bowel habit was unchanged in the placebo group, while constipation significantly improved in patients taking ispaghula (p = 0.026). Transit time decreased significantly in those taking ispaghula compared with placebo (p = 0.001), especially in patients with initially high transit times. Abdominal pain and bloating improved in both groups, with no significant differences between ispaghula and placebo. Four of the eight withdrawals on ispaghula and 10 of the 15 withdrawals on placebo were because of treatment failure. Ispaghula significantly improves overall well being in patients with irritable bowel syndrome, and in those with constipation favourably affects bowel habit and transit time.
本文报道了一项针对80例肠易激综合征患者的关于卵叶车前草籽壳的双盲安慰剂对照试验。整体评估显示，接受卵叶车前草籽壳治疗的患者中有82%对治疗满意，而安慰剂组这一比例为53%（p<0.02）。安慰剂组的排便习惯未改变，而服用卵叶车前草籽壳的患者便秘情况显著改善（p = 0.026）。与安慰剂组相比，服用卵叶车前草籽壳的患者转运时间显著缩短（p = 0.001），尤其是初始转运时间较长的患者。两组患者的腹痛和腹胀情况均有所改善，卵叶车前草籽壳组与安慰剂组之间无显著差异。服用卵叶车前草籽壳的8例退出研究患者中有4例，服用安慰剂的15例退出研究患者中有10例是因为治疗失败。卵叶车前草籽壳能显著改善肠易激综合征患者的整体健康状况，对于便秘患者，它能有利地影响排便习惯和转运时间。
